13therapeutics is a research and drug development company focused on identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has developed an innovative platform for discovering and enhancing peptides derived from naturally occurring pathogens, which modulate the human immune response. This has resulted in a portfolio of peptides with demonstrated immune-regulatory activity and varying mechanisms of action.
These peptides have potential applications in the treatment of both acute and chronic inflammatory diseases. They can be delivered through multiple methods, show serum stability, and possess other desired features for clinical therapeutics. Target conditions include acute inflammatory diseases such as Acute Otitis Media (AOM), Systemic Inflammation, Meningitis, Traumatic Brain Injury (TBI), Uveitis, and Ischemia. The company is also evaluating peptides in chronic models for conditions like Lupus, Rheumatoid Arthritis (RA), Multiple Sclerosis, Atherosclerosis, Crohn’s Disease, and Psoriasis, leveraging its evolution-based methodology for rapid development across several disease states.
Founded in 2008, 13therapeutics operates in the Health Care industry. The company's last investment was a $3.00M grant investment on 21 January 2011 from the NSF Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR).
